{"name":"Catalyst Biosciences","slug":"catalyst-bio","ticker":"CBIO","exchange":"NASDAQ","domain":"catalystbiosciences.com","description":"Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.","hq":"South San Francisco, CA","founded":0,"employees":"44","ceo":"Nassim Usman","sector":"Hematology / Complement Biotech","stockPrice":17.65,"stockChange":-1.56,"stockChangePercent":-8.12,"marketCap":"$537M","metrics":{"revenue":275000,"revenueGrowth":116.5,"grossMargin":100,"rdSpend":13698000,"netIncome":9880000,"cash":213192000,"dividendYield":0,"peRatio":-4.9,"fiscalYear":"FY2014"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"marzAA patent cliff ($0.0B at risk)","drug":"marzAA","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Catalyst Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Catalyst Biosciences reported its fourth quarter and full year 2023 financial results, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Catalyst Biosciences Announces $20 Million Private Placement Financing","summary":"Catalyst Biosciences announced a $20 million private placement financing to support the development of its marzAA program.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Catalyst Biosciences Announces Positive Topline Results from Phase 1/2 Clinical Trial of MarzAA in Hemophilia A","summary":"Catalyst Biosciences announced positive topline results from its Phase 1/2 clinical trial of marzAA in hemophilia A, with significant reductions in bleeding rates.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNeWJGX3A2ZThjSlJDTTRCSzRRaUVrTlk4YnJSTHNwT1JXOE5KQm93cnlhaG1iMl9FVlNBeUVjZTZlbWJldDBReG5vRTVmV0FMMk94TUtpZTZEaUJiQkxBQUpLSWItQWhvQ2lCZGwxSjJqZmg1bkFoT2dhelNxR1ZVSGxCWU9HS2s3UndFUk9ZTQ?oc=5","date":"2025-12-17","type":"pipeline","source":"BioSpace","summary":"6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace","headline":"6 Biotechs That Could Be Big Pharma’s Next M&A Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQeXdrVl85MjhnTXViMVJ0YU1qR2licjltc1JPRTZSU1V0empyRHdaUkJFWHc3a21lVG1IckV3aWNILXlyME1GelZEcXNVVXJnM0dGaG84RUlBTUJZdG5IZzNEaFpYWkRjLWdLM2dqZHN1R1RaSGs5VW8tLUltODVTSHJGbkdwVEE?oc=5","date":"2025-12-16","type":"deal","source":"businessrecord.com","summary":"Corteva, Hexagon Bio create ag-pharma partnership - businessrecord.com","headline":"Corteva, Hexagon Bio create ag-pharma partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQMUhiT3N0WWtpcXlFWFlYT3F6c0E5LXhoMjEwdnBjMTRLYzJPc0Uzbk9ma3Q3NnpUOVFiNnZRLU8wXzdERDRlc2U0SlhSek9ORWs4QWRLb2pubW5lZnJJMjFCbGxybjVTWENLWU5oYV9WZjVnaUlxX3Ryd2d6ZHN6d1FLVmpqaU41d3h4Q2M5YzhCNHVBQW9HMHpzVQ?oc=5","date":"2025-12-10","type":"trial","source":"globaldata.com","summary":"Bio/Pharmaceutical Outsourcing Report, November 2025 - globaldata.com","headline":"Bio/Pharmaceutical Outsourcing Report, November 2025","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPRE9rTmRWTjEtN21RRk5JN045YU5vcWxzSVh0eHVIRWk0X205Mml2UDh6VDlELVRGclpYaTNmUF82eE1fT0R5Z1NaTlVFWDZlRzRfTFJySzF3ZVpDV0s4MmJ3bS1iR0l2V1lvLWxsbWFyMnljVFlaVW5PeHJwbThZaGxIbGl6LTR1NFlTRno2UDA3S2lDaW5rSWFpMHg?oc=5","date":"2025-10-24","type":"trial","source":"Endpoints News","summary":"Novo Nordisk lines up corporate affairs exec, overshadowed by board drama - Endpoints News","headline":"Novo Nordisk lines up corporate affairs exec, overshadowed by board drama","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZWZmdEYtVlVNbTdNM0dFcVhYWU1SUFdRak0xd3JfZlF6Vk1Td2lod2ZmOTVxYkdZNkFTUDE1RDRzbHNCcmJFTjAtNC1CVnJlWjV4enp6V2p6dGNTQmg4ajRBZUpWVXQweHhhV0dfVjJlWG1HZEFMY0hIQ2pFdzBocUE4d1JfOGZjaGpMbW1QVWRxdw?oc=5","date":"2025-09-22","type":"pipeline","source":"Fierce Biotech","summary":"Introducing Fierce Biotech's 2025 Fierce 15 - Fierce Biotech","headline":"Introducing Fierce Biotech's 2025 Fierce 15","sentiment":"neutral"}],"patents":[{"drugName":"marzAA","drugSlug":"anti-hemophilic-factor","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bioverativ","Baxalta","CSL Behring"],"therapeuticFocus":["Hematology","Complement Biotech"],"financials":{"source":"sec_edgar","revenue":275000,"revenuePeriod":"2014-12-31","revenueHistory":[{"value":275000,"period":"2014-12-31"},{"value":127000,"period":"2014-12-31"},{"value":25000,"period":"2014-09-30"},{"value":36000,"period":"2014-06-30"},{"value":87000,"period":"2014-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13698000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":9880000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":166132000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.65,"previousClose":19.21,"fiftyTwoWeekHigh":29,"fiftyTwoWeekLow":8.72,"fiftyTwoWeekRange":"8.72 - 29.0","fiftyDayAverage":11.81,"twoHundredDayAverage":12.75,"beta":0,"enterpriseValue":430490784,"forwardPE":-4.9,"priceToBook":2.95,"priceToSales":49.56,"enterpriseToRevenue":39.7,"enterpriseToEbitda":-2.82,"pegRatio":0,"ebitda":-152548000,"ebitdaMargin":0,"freeCashflow":-153697632,"operatingCashflow":-71532000,"totalDebt":1644000,"debtToEquity":0.8,"currentRatio":6.56,"returnOnAssets":-69.1,"returnOnEquity":-160.7,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":29.29,"targetHighPrice":35,"targetLowPrice":22,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.8,"institutionHeldPercent":87.5,"sharesOutstanding":27556767,"floatShares":14421470,"sharesShort":1447809,"shortRatio":8.51,"shortPercentOfFloat":4.8,"epsTrailing":-12.81,"epsForward":-3.58,"revenuePerShare":0.9,"bookValue":5.99,"officers":[{"age":47,"name":"Mr. Joshua T. Brumm","title":"CEO & Director"},{"age":39,"name":"Dr. Jonathan  McNeill M.D.","title":"President & COO"},{"age":46,"name":"Dr. Ellie  Im M.D.","title":"Chief Medical Officer"},{"age":38,"name":"Mr. Richard William Scalzo M.B.A.","title":"Chief Financial Officer"},{"age":40,"name":"Mr. Ryan  Lynch","title":"Senior VP of Finance, Treasurer & Chief Accounting Officer"},{"age":null,"name":"Dr. Wenjie  Cheng Ph.D.","title":"Senior Vice President of Technical Operations"},{"age":56,"name":"Dr. Jan  Pinkas Ph.D.","title":"Chief Scientific Officer"},{"age":38,"name":"Ms. Barbara H. Bispham J.D.","title":"General Counsel & Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://crescentbiopharma.com","phone":"617 460 5595"}}